<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00153673</url>
  </required_header>
  <id_info>
    <org_study_id>5NA study</org_study_id>
    <nct_id>NCT00153673</nct_id>
  </id_info>
  <brief_title>Effect of Selective COX-2 Inhibition on Ulcer Healing</brief_title>
  <official_title>Phase III Study of a Double-Blind Randomized Comparison of Famotidine Plus Celecoxib Versus Dologesics for Gastric Ulcer Healing in Arthritis Patients (NSAID#5A Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of Famotidine plus a COX-2 inhibitor&#xD;
      (celecoxib) with Famotidine plus dologesics in ulcer healing in arthritis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For many years the integrity of the stomach mucosal barrier is thought to be maintained by&#xD;
      mucosal prostaglandins (PG) synthesized by COX-1. However, the notion that COX-1 protects the&#xD;
      stomach and COX-2 induces inflammation may be over-simplistic. In animal studies, COX-2, but&#xD;
      not COX-1, is expressed in experimental gastric ulcer. Inhibition of COX-2 delays ulcer&#xD;
      healing, indicating that PG derived from COX-2 contributes to restoring the mucosal barrier&#xD;
      [1]. Whether this animal observation can be generalized to the human stomach is unknown. To&#xD;
      date the biological functions of COX-1 and COX-2 in the healing of human gastric ulcer&#xD;
      healing is unclear. Unlike experimental ulcers that only express COX-2, recently we have&#xD;
      shown that both COX-1 and COX-2 are up-regulated in human gastric ulcers [2]. Furthermore,&#xD;
      our preliminary results suggest that inhibition of COX-2 alone may not lead to a clinically&#xD;
      significant delay in ulcer healing (refer to progress report). These observations suggest&#xD;
      that peptic ulcer healing is more complex in the human stomach - both COX isoforms may be&#xD;
      involved in the healing process. Inhibition of COX-2 alone may have less adverse effect than&#xD;
      non-selective inhibition of both COX isoforms in ulcer healing. The current study aims to&#xD;
      resolve the functional significance of COX-2 in human gastric ulcer from a biological and&#xD;
      clinical perspective.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">April 12, 2017</completion_date>
  <primary_completion_date type="Actual">December 28, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ulcer healing</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Arthritis</condition>
  <condition>Gastric Ulcer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib + Famotidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dologesics + Famotidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>Celecoxib 200mg bd</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dologesics</intervention_name>
    <description>Dologesics 2 tablets bd</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gastric ulcers confirmed by endoscopy&#xD;
&#xD;
          -  Stop taking NSAIDs for 1 week prior to endoscopy&#xD;
&#xD;
          -  Age 18&#xD;
&#xD;
          -  H. pylori negative&#xD;
&#xD;
          -  Informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Actively bleeding ulcers&#xD;
&#xD;
          -  Ulcers showing dysplasia or malignancy&#xD;
&#xD;
          -  Renal failure (serum creatinine &gt;200umol/l)&#xD;
&#xD;
          -  Previous gastric surgery&#xD;
&#xD;
          -  Moribund or terminal malignancy&#xD;
&#xD;
          -  Concomitant use of proton pump inhibitor, misoprostol, aspirin, steroid or&#xD;
             anticoagulant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis K Chan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endoscopy Center, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Francis KL Chan</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>celecoxib</keyword>
  <keyword>arthritis</keyword>
  <keyword>ulcer healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

